Literature DB >> 10386469

Fas antigen/CD-95 upregulation and activation during castration-induced regression of the rat ventral prostate gland.

A de la Taille1, M W Chen, A Shabsigh, E Bagiella, A Kiss, R Buttyan.   

Abstract

BACKGROUND: Fas antigen/CD 95 is a 45-kDa transmembrane protein that can initiate intracellular signaling pathways, leading to apoptosis when it is clustered on the cell surface. A recent report claiming that the ventral prostate glands of lpr -/- mutant mice (lacking functional fas antigen) do not regress following castration prompted our analysis of the regressing rat ventral prostate gland for evidence that fas antigen might participate in the molecular process leading to prostate cell apoptosis after castration.
METHODS: An RNase protection assay and Western blotting analysis were used to quantify fas antigen mRNA and protein expression in the regressing rat ventral prostate gland. Immunoprecipitates of fas antigen from membrane preparations made from control or castrated rat prostates were analyzed for coprecipitation of FADD and RIP proteins to assess the activation state of the fas antigen before and after castration. Finally, prostate tissues obtained from two different strains of lpr -/- mutant mice were analyzed for induced apoptosis after castration by the TUNEL staining method.
RESULTS: Rat ventral prostate gland fas antigen mRNA and protein expression was upregulated approximately 3-5-fold in the 3-day castrated rat as compared to hormonally intact rats. Immunoprecipitates of fas antigen from membranes of ventral prostates from castrated rats contained significantly increased amounts of both FADD and RIP proteins when compared to those of intact or control operated rats. However, counts of TUNEL-labeled cells in the ventral prostate glands of castrated lpr -/- mice were not significantly different from those in castrated, genetically normal controls. Likewise, the morphology of apoptotic bodies formed in the prostates of castrated lpr -/- mice was indistinguishable from that in control animals.
CONCLUSIONS: Fas antigen/CD-95, a protein that is involved in some forms of apoptosis, is upregulated during regression of the rat ventral prostate gland and becomes functionally "activated." However, our inability to distinguish any difference in the apoptosis rate or in the morphology of the apoptotic bodies formed in response to castration between lpr -/- mice and genetically normal controls indicates that, contrary to the prior report, functional fas protein is not required for castration-induced prostate cell apoptosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10386469     DOI: 10.1002/(sici)1097-0045(19990701)40:2<89::aid-pros4>3.0.co;2-e

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  5 in total

1.  Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer.

Authors:  Kathrine Røe; Lars Tg Mikalsen; Albert J van der Kogel; Johan Bussink; Heidi Lyng; Anne H Ree; Laure Marignol; Dag R Olsen
Journal:  Radiat Oncol       Date:  2012-05-23       Impact factor: 3.481

2.  TNF is necessary for castration-induced prostate regression, whereas TRAIL and FasL are dispensable.

Authors:  Jennifer S Davis; Kent L Nastiuk; John J Krolewski
Journal:  Mol Endocrinol       Date:  2011-02-03

3.  Down-regulation of DcR2 sensitizes androgen-dependent prostate cancer LNCaP cells to TRAIL-induced apoptosis.

Authors:  David Vindrieux; Marie Réveiller; Jacqueline Chantepie; Sadok Yakoub; Catherine Deschildre; Alain Ruffion; Marian Devonec; Mohamed Benahmed; Renée Grataroli
Journal:  Cancer Cell Int       Date:  2011-12-02       Impact factor: 5.722

4.  Carbogen gas and radiotherapy outcomes in prostate cancer.

Authors:  Kent Yip; Roberto Alonzi
Journal:  Ther Adv Urol       Date:  2013-02

5.  In vivo MRI volumetric measurement of prostate regression and growth in mice.

Authors:  Kent L Nastiuk; Hui Liu; Mark Hamamura; L Tugan Muftuler; Orhan Nalcioglu; John J Krolewski
Journal:  BMC Urol       Date:  2007-07-24       Impact factor: 2.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.